In a previous blog post, I took a look at Western blots in papers from the lab of Dr. Hoau-Yan Wang at City University of New York (CUNY), mostly related to Cassava Sciences (Nasdaq: $SAVA), its predecessor Pain Therapeutics INC, and its flagship Alzheimer's Disease drug candidate Simufilam.

While those papers were about the preclinical Simufilam data, here I will take a look at a conference poster which reports about Phase 2 data obtained by Cassava Sciences.

Read more of this post

eliesbik | August 30, 2021 at 8:54 am | Categories: Uncategorized | URL: https://wp.me/pb0gey-IG
Comment        Like